Technical Analysis for NBY - NovaBay Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.6879 30.04% 0.16
NBY closed up 30.04 percent on Wednesday, September 18, 2019, on 6.08 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical NBY trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Resistance Bearish 30.04%
Wide Bands Range Expansion 30.04%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 32.21%
Inside Day Range Contraction 32.21%

Older signals for NBY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company's Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Medicine Biotechnology Health California Pharmaceutical Products Catheter Acne Urinary Tract Infections Impetigo
Is NBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.04
52 Week Low 0.1
Average Volume 1,006,180
200-Day Moving Average 1.1349
50-Day Moving Average 0.8922
20-Day Moving Average 0.5515
10-Day Moving Average 0.5182
Average True Range 0.1035
ADX 18.68
+DI 30.8915
-DI 18.6317
Chandelier Exit (Long, 3 ATRs ) 0.4395
Chandelier Exit (Short, 3 ATRs ) 0.7315
Upper Bollinger Band 0.6931
Lower Bollinger Band 0.4099
Percent B (%b) 0.98
BandWidth 51.350861
MACD Line -0.0954
MACD Signal Line -0.1319
MACD Histogram 0.0365
Fundamentals Value
Market Cap 10.53 Million
Num Shares 15.3 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -0.87
Price-to-Sales 4.39
Price-to-Book 20.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.97
Resistance 3 (R3) 0.96 0.85 0.92
Resistance 2 (R2) 0.85 0.78 0.86 0.91
Resistance 1 (R1) 0.77 0.74 0.81 0.78 0.89
Pivot Point 0.67 0.67 0.69 0.67 0.67
Support 1 (S1) 0.58 0.59 0.62 0.59 0.48
Support 2 (S2) 0.48 0.55 0.48 0.47
Support 3 (S3) 0.40 0.48 0.45
Support 4 (S4) 0.41